Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience.
作者信息
Pinchera Biagio, Buonomo Antonio Riccardo, Scotto Riccardo, Carrano Rosa, Salemi Fabrizio, Galluccio Fabiana, Guarino Maria, Viceconte Giulio, Schiano Moriello Nicola, Giaccone Agnese, Gallicchio Antonella, Zappulo Emanuela, Villari Riccardo, Gentile Ivan
机构信息
Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II," Naples, Italy.
Department of Public Health, Section of Nephrology, University of Naples "Federico II," Naples, Italy.
出版信息
Transplantation. 2022 Jul 1;106(7):e343-e345. doi: 10.1097/TP.0000000000004150. Epub 2022 Mar 24.
Abstract
摘要
相似文献
1
Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience.索托维单抗治疗实体器官移植患者早期轻/中度严重急性呼吸综合征冠状病毒2感染：单中心经验
Transplantation. 2022 Jul 1;106(7):e343-e345. doi: 10.1097/TP.0000000000004150. Epub 2022 Mar 24.
2
Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.贝特洛维单抗和索特罗维单抗治疗奥密克戎纪元中 COVID-19 轻症至中症的实体器官移植受者的结局。
Transpl Infect Dis. 2022 Aug;24(4):e13901. doi: 10.1111/tid.13901. Epub 2022 Jul 25.
3
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.奥密克戎变异株流行期间，实体器官移植受者中可获得的门诊 COVID-19 治疗的真实世界经验。
Am J Transplant. 2022 Oct;22(10):2458-2463. doi: 10.1111/ajt.17098. Epub 2022 May 30.
4
Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients.COVID-19 单克隆抗体治疗在实体器官移植受者中的应用。
Transpl Infect Dis. 2022 Feb;24(1):e13759. doi: 10.1111/tid.13759. Epub 2021 Dec 7.
5
Sotrovimab for Treatment of COVID-19 in Solid Organ Transplant Recipients.索托维单抗用于实体器官移植受者的新冠治疗
Transplantation. 2022 Jul 1;106(7):e336-e337. doi: 10.1097/TP.0000000000004136. Epub 2022 Apr 15.
6
Sotrovimab in pediatric cardiac transplant recipients with SARS-CoV2 infection.索托维单抗在感染新冠病毒的小儿心脏移植受者中的应用。
J Heart Lung Transplant. 2022 Aug;41(8):1124-1126. doi: 10.1016/j.healun.2022.05.003. Epub 2022 May 20.
7
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.COVID-19 于实体器官移植受者：来自美国震中地区的初步报告。
Am J Transplant. 2020 Jul;20(7):1800-1808. doi: 10.1111/ajt.15941. Epub 2020 May 10.
8
Casirivimab-imdevimab to Prevent SARS-CoV-2 Infections in Solid Organ Transplant Recipients.卡西瑞维单抗-英夫西单抗预防实体器官移植受者感染严重急性呼吸综合征冠状病毒2
Transplantation. 2022 May 1;106(5):e275-e276. doi: 10.1097/TP.0000000000004087. Epub 2022 Mar 8.
9
Sotrovimab Use for COVID-19 Infection in Pregnant Kidney Transplant Recipient.索托维单抗在妊娠肾移植受者新冠病毒感染中的应用
Transplantation. 2022 May 1;106(5):e277-e278. doi: 10.1097/TP.0000000000004083. Epub 2022 Feb 4.
10
Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.SARS-CoV-2 疫苗接种后突破 COVID-19 在实体器官移植受者中的发生：症状病例分析和单克隆抗体治疗。
Transpl Infect Dis. 2022 Apr;24(2):e13779. doi: 10.1111/tid.13779. Epub 2022 Jan 31.
引用本文的文献
1
COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study.疫情两年后实体器官移植受者的新冠肺炎：单中心研究中抗病毒治疗的结果及影响
Front Transplant. 2023 Mar 16;2:1095225. doi: 10.3389/frtra.2023.1095225. eCollection 2023.
2
Prevention and treatment strategies for kidney transplant recipients in the context of long-term existence of COVID-19.新冠病毒长期存在背景下肾移植受者的预防和治疗策略
Front Med (Lausanne). 2024 Apr 3;11:1287836. doi: 10.3389/fmed.2024.1287836. eCollection 2024.
3
What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study.在奥密克戎时代，索特罗维单抗在降低 COVID-19 患者疾病进展和死亡方面的疗效如何？一项真实研究的答案。
Viruses. 2023 Aug 17;15(8):1757. doi: 10.3390/v15081757.
4
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2.专家共识：影响 COVID-19 预后不良的主要危险因素及其对靶向 SARS-CoV-2 措施的影响。
Viruses. 2023 Jun 27;15(7):1449. doi: 10.3390/v15071449.
5
Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies.降低 SARS-CoV-2 感染的实体器官移植受者进展为重症的风险：单克隆抗体治疗的作用
Rev Esp Quimioter. 2023 Aug;36(4):380-391. doi: 10.37201/req/023.2023. Epub 2023 Apr 24.
6
Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.尼马曲韦/利托那韦治疗 SARS-CoV-2 阳性肾移植受者 - 四例病例系列。
BMC Nephrol. 2023 Apr 15;24(1):99. doi: 10.1186/s12882-023-03154-w.
7
Disease Course, Management and Outcomes in Kidney Transplant Recipients with SARS-CoV-2 Infection during the Omicron-Variant Wave: A Single-Center Experience.奥密克戎变异株流行期间感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的肾移植受者的病程、管理及结局：单中心经验
Vaccines (Basel). 2023 Mar 12;11(3):632. doi: 10.3390/vaccines11030632.
8
The COVID-19 Pandemic and Adult Cardiac Transplantation: Impact, Interventions, and Implications.《COVID-19 大流行与成人心脏移植：影响、干预及意义》
Can J Cardiol. 2023 Jun;39(6):853-864. doi: 10.1016/j.cjca.2023.03.014. Epub 2023 Mar 23.
9
COVID-19 mortality may be reduced among fully vaccinated solid organ transplant recipients.COVID-19 死亡率可能会降低在完全接种疫苗的实体器官移植受者中。
PLoS One. 2022 Dec 21;17(12):e0279222. doi: 10.1371/journal.pone.0279222. eCollection 2022.
10
Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge.抗新型冠状病毒2感染的单克隆抗体：奥密克戎毒株激增前的一项真实研究结果
Vaccines (Basel). 2022 Nov 10;10(11):1895. doi: 10.3390/vaccines10111895.
Zotero 插件